Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have moved upward following the release of preliminary fiscal-year 2025 revenue results disclosed after market hours on Tuesday. The company revealed significant progress in its financial performance, projecting a strong growth trajectory heading into 2026.
For the full year 2025, TG Therapeutics reported estimated total global revenue of approximately $616 million. A notable contributor to this figure was the U.S. net product revenue for BRIUMVI, which registered roughly $182 million in the last quarter and totaled about $594 million for the year. These preliminary financial figures remain unaudited and are subject to final verification and closing procedures.
Looking forward, TG Therapeutics provided guidance for fiscal 2026, anticipating total global revenue in the range of $875 million to $900 million. Within this projection, U.S. net product revenue for BRIUMVI is expected to be between $825 million and $850 million, marking a significant increase and underscoring the product's critical role in the company's revenue mix.
The company also detailed anticipated operating expenditures for the coming year, estimating approximately $350 million in operating expenses excluding non-cash compensation. Additional forecasted expenses include close to $100 million related to the build-up of subcutaneous BRIUMVI inventory and startup costs associated with a secondary manufacturer, reflecting investments aimed at future production capacity enhancement and supply chain diversification.
TG Therapeutics outlined key developmental milestones anticipated throughout 2026. Among these are the release of mid-year topline data from the ENHANCE trial, which is investigating consolidated intravenous dosing of BRIUMVI. Further into the year, the company expects preliminary Phase 1 data for azer-cel in progressive multiple sclerosis, projected for the second half of 2026. Near year-end 2026 or possibly extending into the first quarter of 2027, topline results for the subcutaneous formulation of BRIUMVI are anticipated, signaling important potential enhancements in the product's administration and patient convenience.
Turning to technical analysis, TG Therapeutics' stock performance shows a complex pattern with both encouraging and cautionary signals. The stock price currently sits 1.7% above its 20-day simple moving average (SMA), indicating some short-term strength. However, it struggles beneath longer-term averages, specifically 1.6% below the 50-day SMA, 5% below the 100-day SMA, and 10.3% below the 200-day SMA. These positions suggest that the broader trend remains bearish.
The Relative Strength Index (RSI) currently reads 34.82, which falls within a neutral range but leans toward oversold conditions. This metric indicates that while momentum is weak, the stock may be nearing a point where buyers could gain interest if sentiment shifts positively. Conversely, the Moving Average Convergence Divergence (MACD) indicator stands below its signal line, reflecting ongoing bearish momentum and signaling that downward pressure may persist absent a significant catalyst or increased buying volume.
Key price levels to monitor include strong support at $30.00 and resistance at $34.00. Should the stock test and fail to maintain the $30.00 support level, further declines could ensue. Conversely, a successful breach above resistance at $34.00 might suggest the beginnings of a positive trend reversal. Investors and traders should observe these thresholds closely as they may provide actionable insights regarding the stock's trajectory.
It is relevant to note that in August, TG Therapeutics experienced a technical event known as a "death cross," where the 50-day SMA fell below the 200-day SMA. This pattern traditionally signals bearish market conditions and calls for cautious trading, reinforcing the current downward momentum observed in the stock.
Over the past 12 months, TG Therapeutics shares have declined by 6.29%, which encapsulates the ongoing challenges the stock faces within the broader market environment. Positioned near 25.1% of its 52-week range, the stock remains significantly closer to its yearly lows than its highs, indicating subdued market sentiment and a cautious outlook from investors.
Overall, the technical indicators and historical price movements suggest that TG Therapeutics remains in a predominantly bearish phase, albeit with potential for some recovery as reflected by short-term momentum signals. Close attention to critical support and resistance levels, alongside forthcoming company developments, will be essential in gauging future performance.
As of the latest trading session, TG Therapeutics shares were trading approximately 11.23% higher at $31.00, marking a notable intraday increase in response to the company's fiscal disclosures.